阿托伐醌诱导的非小细胞肺癌肿瘤缺氧空间变化的缺氧PET/CT研究
ATOM试验纳入可切除非小细胞肺癌患者,队列1(n=15)接受阿托伐醌治疗,队列2(n=15)未接受。缺氧PET/CT显示阿托伐醌诱导的肿瘤缺氧减少主要发生在肿瘤内部和外部亚区,中央亚区程度较轻,边缘亚区未见明显作用。缺氧最严重的体素缺氧下降最明显。
要点
- 阿托伐醌诱导的肿瘤缺氧减少主要见于肿瘤内部和外部亚区。
- 中央亚区缺氧减少程度较轻,边缘亚区未见明显作用。
- 基线缺氧最严重、放射生物学抵抗最强的体素缺氧下降最明显。
核心结论
- 本研究揭示了阿托伐醌在肿瘤各亚区的作用,有助于理解其作为新型肿瘤放射增敏剂的作用。
研究设计与样本
- ATOM试验(NCT02628080)纳入可切除非小细胞肺癌患者,队列1(n=15)接受阿托伐醌治疗,队列2(n=15)未接受。
- 使用缺氧PET成像评估平均肿瘤-血比值变化、肿瘤缺氧体积和缺氧体素比例等指标。
- 用MATLAB将肿瘤分为边缘、外部、内部和中央四个亚区或距离类别。
主要发现
- 阿托伐醌诱导的肿瘤缺氧减少主要发生在内部和外部亚区,中央亚区程度较轻。
- 阿托伐醌在边缘亚区似乎未见作用,该亚区是基线时唯一非缺氧的肿瘤亚区。
- 在不同亚区中,缺氧最严重、放射生物学抵抗最强的肿瘤体素缺氧下降最明显。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tumour hypoxia promotes an aggressive tumour phenotype and enhances resistance to anticancer treatments. Following the recent observation that the mitochondrial inhibitor atovaquone increases tumour oxygenation in NSCLC, we sought to assess whether atovaquone affects tumour subregions differently depending on their level of hypoxia. METHODS: Patients with resectable NSCLC participated in the ATOM trial (NCT02628080). Cohort 1 (n = 15) received atovaquone treatment, whilst cohort 2 (n = 15) did not. Hypoxia-related metrics, including change in mean tumour-to-blood ratio, tumour hypoxic volume, and fraction of hypoxic voxels, were assessed using hypoxia PET imaging. Tumours were divided into four subregions or distance categories: edge, outer, inner, and centre, using MATLAB. RESULTS: Atovaquone-induced reduction in tumour hypoxia mostly occurred in the inner and outer tumour subregions, and to a lesser extent in the centre subregion. Atovaquone did not seem to act in the edge subregion, which was the only tumour subregion that was non-hypoxic at baseline. Notably, the most intensely hypoxic tumour voxels, and therefore the most radiobiologically resistant areas, were subject to the most pronounced decrease in hypoxia in the different subregions. CONCLUSIONS: This study provides insights into the action of atovaquone in tumour subregions that help to better understand its role as a novel tumour radiosensitiser. TRIAL REGISTRATION: ClinicalTrials.gov, NCT0262808. Registered 11th December 2015, https://clinicaltrials.gov/ct2/show/NCT02628080.
引用
- Bourigault P, Skwarski M, Macpherson RE, et al. Investigation of atovaquone-induced spatial changes in tumour hypoxia assessed by hypoxia PET/CT in non-small cell lung cancer patients. EJNMMI Res. 2021. PMID: 34964932. doi:10.1186/s13550-021-00871-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。